Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed head and neck squamous
             cell carcinoma including cutaneous squamous cell cancer of the head and neck.

          -  Measurable disease by scans- at least one measurable lesion.

          -  Patients must have received previous treatment with immunotherapy with PD-1 inhibitor
             alone or in combination with chemotherapy in the last 6 months.

          -  Patients must have a Performance Status of 0-2.

          -  Patients must be greater than or equal to 18 years old.

          -  Willing to provide consent for collection of samples of blood and saliva as scheduled
             through the treatment.

          -  Subject is willing and able to comply with the protocol for the duration of the study.

          -  Willingness to donate 2 tablespoons of blood and one teaspoon of saliva before
             treatment, 4 times during the first 6 weeks of treatment and then every 6-8 weeks
             while patients is under treatment.

          -  Ability to understand and the willingness to sign an Institutional Review
             Board-approved informed consent document.

        Exclusion Criteria:

          -  Prior treatment with Cetuximab or prior therapy that specifically and directly targets
             the epidermal growth factor receptor (EGFR) pathway.

          -  Prior allergic reaction to Cetuximab.

          -  History of allergic reactions attributed to compounds of chemical or biologic
             composition similar to those of cetuximab.

          -  Patients receiving any other investigational agents.

          -  Patient is on medications that need to be continued and that might interact with
             Cetuximab.

          -  Any uncontrolled condition, which in the opinion of the investigator, would interfere
             in the safe and timely completion of study treatment and procedures.

          -  Subject with a history of interstitial lung disease (e.g. pneumonitis or pulmonary
             fibrosis) or evidence of interstitial lung disease on screening chest imaging.

          -  Any of the following conditions: Serious or non-healing wound, ulcer, or bone
             fracture, history of abdominal fistula, gastrointestinal perforation, or
             intra-abdominal abscess within 28 days of study enrollment, history of cerebrovascular
             accident (CVA) or transient ischemic attack within 12 months prior to study
             enrollment, history of myocardial infarction, ventricular arrhythmia, stable/unstable
             angina, -symptomatic congestive heart failure, coronary/peripheral artery bypass graft
             or stenting or other significant cardiac disease within 6 months prior to study
             enrollment, history of arterial or venous thrombosis/thromboembolic event, including
             pulmonary embolism within 6 months of study enrollment, any condition requiring the
             use of immunosuppression, excluding rheumatologic conditions treated with stable doses
             of corticosteroids.

          -  Pregnancy, breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the screening visit through 6 months
             after the last dose of trial treatment.